BofA upgraded GSK (GSK) to Neutral from Underperform with a price target of 2,000 GBp, up from 1,700 GBp. GSK has a busy and “contentious” FY26 with two launches – Blenrep and Depemokimab – and three key pipeline events, the analyst tells investors. These events all help shape a “narrative of growth” in the specialty business potentially being sufficient to offset the HIV patent cliff, the analyst added.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GlaxoSmithKline’s Mixed Outlook: Balancing Product Launches and Patent Challenges
- RFK told CDC to change website language on autism and vaccines, NYT reports
- Video: Gap jumps after strong comparable sales growth
- AnaptysBio initiates litigation against GSK subsidiary Tesaro
- GSK subsidiary initiates litigation against AnaptysBio